Key Takeaway: New FDA guidance released on February 23, 2026, and March 9, 2026, signals a continued shift toward regulatory flexibility aimed at accelerating approval of biosimilar treatments for rare and ultra-rare diseases.
The U.S. Food and Drug Administration (FDA)[1] released new guidance on February 23, 2026, which appears designed to embrace regulatory flexibility in order to allow accelerated access to therapies for patients with rare and ultra‑rare diseases.[2] This new guidance may accelerate the development of individualized therapies for rare and ultra‑rare diseases by allowing biosimilar sponsors to pursue full approval for their product even where randomized controlled trials are infeasible.[3]
Under a new “plausible mechanism” framework announced in the guidelines, the FDA aims to remove barriers, encourage scientific advances, and deliver more cures and meaningful treatments for patients suffering from rare diseases, by aligning regulation with what modern biology can reliably demonstrate.[4] Rather than defaulting to large, resource-intensive clinical trials, the FDA will evaluate therapies that directly target a defined genetic, cellular, or molecular abnormality based on mechanistic evidence, well‑characterized natural history data, and focused clinical or biomarker endpoints. The stated goal of the February guidance is to encourage scientific innovation while delivering meaningful treatments more rapidly to patients with rare and ultra‑rare diseases. This process will allow data generated from individualized therapies for well-characterized, identifiable molecular or cellular abnormalities to support approval under existing regulatory approval pathways without the requirement of extensive clinical trials.
That same philosophy underlies the FDA’s March 9th biosimilar guidance, which recommends eliminating, or substantially narrowing, clinical pharmacokinetic (PK) studies where analytical and functional data are sufficient to establish biosimilarity.[5] According to the FDA, this recalibration could reduce biosimilar development costs by up to 50%.
The March 9th guidance indicates that the FDA will expand its acceptance of non‑U.S.‑licensed comparator data. According to the March guidance, clinical trial data from outside the U.S. may be used in place of a three-way pharmacokinetic study comparing the proposed biosimilar, the U.S. reference product, and the comparator product. The guidance also removes the requirement for a direct comparison of the proposed biosimilar with the U.S. licensed product.
Together, these two changes are expected to streamline biosimilar development, eliminate clinical requirements for some products, lower the cost of early‑stage biosimilar programs, and enable globally coordinated biosimilar development strategies. Specifically, the FDA’s recent guidance on rare disease and biosimilar reforms reflects a regulatory strategy that compresses the development timeline at both ends of the biologics life cycle, potentially accelerating biosimilar market entry and elevating the strategic importance of robust patent protection in a market projected to exceed $100 billion annually by 2034.[6]
Editor: Brenden S. Gingrich, Ph.D.
[2] See https://www.knobbe.com/blog/rare-disease-therapies-gain-momentum-with-regulatory-support-and-continued-market-growth/
[3] See https://www.hhs.gov/press-room/fda-launches-framework-accelerating-development-individualized-therapies-ultra-rare-diseases.html
[4] See https://www.fda.gov/news-events/press-announcements/fda-launches-framework-accelerating-development-individualized-therapies-ultra-rare-diseases
[5] See https://www.fda.gov/news-events/press-announcements/fda-takes-further-steps-streamline-biosimilar-development-and-make-medicines-more-affordable
[6] See https://www.biospace.com/press-releases/biosimilars-market-size-estimated-to-reach-usd-175-99-billion-by-2034
Subscribe for News and Updates
